Inmed Pharmaceuticals Inc. · NASDAQ:INM
Inmed Pharmaceuticals — Investor Presentation (January 2021)
32 slides from Inmed Pharmaceuticals's investor presentation, Jan 11, 2021
Slide 1: Unlocking the Potential of Cannabinoid Medicines
U N L O C K I N G T H E P O T E N T I A L O F C A N N A B I N O I D M E D I C I N E S Corporate Presentation January 2021 www.inmedpharma.com :IN :I NM
Slide 2: Forward Looking Statements
This presentation contains forward - looking statements and forward - looking information within the meaning of applicable securities laws (collectively, “forward - looking statements”) including, among others, statements concerning: unlocking the full potential of cannabinoid pharmaceuticals; antic
Slide 3: Experienced Executive Team
3 Eric A. Adams, MIBS Chief Executive Officer Bruce S. Colwill, CPA, CA Chief Financial Officer Alexandra Mancini, MSc SVP, Clinical and Regulatory Affairs 30+ years of experience in global biopharma leadership: business development, sales, marketing, and M&A with enGene, QLT, Abbott, Fresenius 25+
Slide 4: A Differentiated Cannabinoid Pharmaceutical Company
4 A Differentiated Cannabinoid Pharmaceutical Company Focused on the Therapeutic Application of Cannabinoids for the Treatment of Diseases with High Unmet Medical Needs Researching the therapeutic potential of rare cannabinoids beginning with cannabinol ( CBN ) Developing IntegraSyn - a flexible, in
Slide 5: An Important and Eventful Year: Highlights from 2020
5 An Important and Eventful Year 5 Corporate Presentation January 2021 Highlights from 2020 INM - 755 in Dermatology Completed 2 Phase 1 human clinical trials (normal and wounded skin) INM - 088 in Ocular Disease Completed in vivo PoC , formulation/delivery studies; Licensed MiDROPS ® delivery techn
Slide 6: The Opportunity & Challenge of Rare Cannabinoids
6 Note: lists are not exhaustive The Opportunity & Challenge of Rare Cannabinoids 100+ Rare Cannabinoids 2 – 20% <1% Major Cannabinoids THC CBD • Epilepsy • Anxiety • Stress Disorder • Pain • Glaucoma • Inflammation • Nausea • Stress Disorder • Sleep Apnea CBN, CBG, CBGA, CBGV, CBGVA, THCV, THCVA, C
Slide 7: Limitations of Traditional Cannabinoid Production Approaches
7 Limitations of Traditional Cannabinoid Production Approaches • Bioburden/stress on microbe may limit final yields • Separation and purification challenges to isolate cannabinoid from mixture • Process costs / complexity increase with each new cannabinoid • May not produce bio - identical cannabino
Slide 8: IntegraSyn: Biosynthesis Evolved
8 IntegraSyn Ρ is InMed’s integrative cannabinoid manufacturing approach IntegraSyn Ρ : Biosynthesis Evolved Minimizes bioburden on fermentation microbe Flexibility to shift from production of one cannabinoid to a range of cannabinoids Optimized steps to produce high - yield, pharma - grade cannabin
Slide 9: Cannabinoid Production with IntegraSyn
9 Cannabinoid Production with IntegraSyn TM E. coli Fermentation Enzymatic Reaction Upstream Processing Downstream Purification Separation of Cannabinoid from Reaction Mixture Enzyme BIOSYNTHESIS Crude Cannabinoid Mixture Drying BIOTRANSFORMATION Further Cannabinoid Production CHEMICAL SYNTHESIS API
Slide 10: Cannabinoid Manufacturing: Competitive Landscape
10 Note: lists are not exhaustive Cannabinoid Manufacturing: Competitive Landscape IntegraSyn TM Yeast Biosynthesis Algae/Other KEY PARTNERSHIPS R&D Commercial A flexible , integrated cannabinoid synthesis approach using a novel enzyme(s) and various standard pharma manufacturing processes to effici
Slide 11: IntegraSyn: High-level Time & Event Schedule
11 GMP – Good Manufacturing Practices IntegraSyn TM : High - level Time & Event Schedule 2020 2021 Biosynthesis PCT patent application filed IntegraSyn TM high - efficiency enzyme PCT patent filed Continue scale - up of IntegraSyn TM process with Almac Research Collaboration with BayMedica for Integ
Slide 12: Global Leader in Cannabinol (CBN) Therapeutic Development
12 Global Leader in Cannabinol (CBN) Therapeutic Development 12 • A rare cannabinoid with unique physiological and safety properties • Found in trace amounts in the plant; impractical to extract, requiring pharmaceutical manufacturing approaches • InMed conducted 30+ preclinical pharmacology and tox
Slide 13: Epidermolysis Bullosa (EB)
13 Epidermolysis Bullosa (EB) 13 • Epidermolysis bullosa (EB) is a group of rare genetic skin diseases characterized by fragile skin that blisters easily from minimal friction that causes shearing of the skin layers. • The most common form is EB Simplex (EBS), ~ 55% of all EB patients . • The affect
Slide 14: INM-755 for Epidermolysis Bullosa: Targeting Disease Hallmarks
14 14 Targeting Disease Hallmarks in A ll EB Patients Evaluate Possible Strengthening of Skin in a Subset of EBS Patients Being Investigated to Deliver Potential Symptomatic Relief: • Reduce i nflammation • Healing of chronic wounds • Pain reduction Other P otential E ffects of C annabinoids: • Itch
Slide 15: INM-755: 30+ Safety Pharmacology and Toxicology Studies
15 INM - 755: 30+ Safety Pharmacology and Toxicology Studies ● CBN - mediated reduction of key inflammatory markers (IL - 8 & MMP - 9) suggests INM - 755 may: o Reduce incidence and/or severity of blistering if applied to intact skin o Improve healing when applied directly to chronic wound ● INM - 7
Slide 16: INM-755: Summary of Completed and Planned Clinical Studies
16 INM - 755: Summary of Completed and Planned Clinical Studies, 2020 - 2021 COMPLETED IN 2020 In Netherlands File CTAs in 1H21 Global Phase I 755 - 101 - HV Phase I 755 - 102 - HV Phase II 755 - 201 - EB Enrollment 22 healthy adult volunteers 8 healthy adult volunteers Up to 20 EB patients (all sub
Slide 17: INM-755 Creams Safe & Well Tolerated on Intact Skin
17 755 - 101 - HV Top - Line Results 17 • Randomized, double - blinded, Ph 1 trial of the safety and tolerability of 14 days of two strengths of INM - 755 cream vs. vehicle on intact skin in 22 healthy adult volunteers. • Specifically examined erythema (redness), edema (fluid accumulation/swelling),
Slide 18: INM-755 Creams Safe & Well Tolerated on Epidermal Wounds
18 755 - 102 - HV Top - Line Results 18 • Randomized, double - blind, Ph 1 trial of the safety and tolerability of 14 days of treatment with INM - 755 cream on epidermal wounds in 8 healthy adult volunteers • Within - subject design with each subject receiving all treatment options on 4 suction blis
Slide 19: Top-Line Results from Phase 1 Healthy Volunteer Studies
19 Top - Line Results from 2 Phase 1 Healthy Volunteer Studies 19 • On intact skin (Study 101, n=22 healthy adult volunteers, 14 days): o Majority of subjects in all groups had no events on most days o Slightly higher incidence and severity of erythema (redness) and scaling (flaking skin) in groups
Slide 20: INM-755: High-Level Time/Event Schedule
20 INM - 755: High - Level Time/Event Schedule Exhibited key preclinical data at EB World Congress Completed enrollment, patient treatment, data analysis and reported results for 755 - 101 - HV Filed CTA in the Netherlands for 755 - 102 - HV Initiated and completed enrollment and treatment in 755 -
Slide 21: Glaucoma Epidemiology & Market Opportunity
21 Glaucoma Epidemiology & Market Opportunity 21 ● There is no current cure for glaucoma o Glaucoma describes a group of conditions in which there is characteristic cupping of the optic disc with corresponding visual field defects due to retinal ganglion cell loss. The common hallmark of glaucoma is
Slide 22: Potential Roles for CBN in Glaucoma
22 Potential Roles for CBN in Glaucoma 22 • Direct neuroprotection for the retina and optical nerve, independent of intraocular pressure (IOP) reduction • Reduce IOP in the affected eyes via increased fluid drainage Target Effects of CBN Build Up of Aqueous Humor Fluid Optic Nerve Pressure Retina Co
Slide 23: INM-088: CBN Ocular Preclinical Studies
23 INM - 088: CBN Ocular Preclinical Studies CBN Preclinical Studies Neuroprotection IOP Reduction RGC 1 Survival under pressure ( in vitro) Effect on RGC apoptosis ( in vitro) Impact on IOP associated biomarkers under pressure conditions ( in vitro ) Neuronal function after CBN Exposure in Glaucoma
Slide 24: INM-088: High-Level Time/Event Schedule
24 INM - 088: High - Level Time/Event Schedule Filed PCT patent for neuroprotection Complete formulation data analysis & select preferred delivery technology Executed license agreement for MiDROPS ® delivery technology with EyeCRO Initiate process development for INM - 088 drug product (CBN + delive
Slide 25: Intellectual Property Portfolio and Commercial Exclusivity
25 Intellectual Property Portfolio and Commercial Exclusivity INM - 755 (EB) INM - 088 (Glaucoma) IntegraSyn TM / Biosynthesis • Topical formulations of cannabinoids and their use in treatment of pain (PCT 2018 ) • A method of treating EBS with cannabinoid or mixture of cannabinoids topically to upr
Slide 26: Business Development: Collaborations
26 Nature of Relationship InMed will explore the therapeutic potential in neuroprotection of specific cannabinoid analog compounds chosen from BayMedica’s library. BayMedica will assess the potential of InMed’s high - efficiency enzymes for the production of cannabinoids in its manufacturing technol
Slide 27: Key Upcoming Milestones
27 Key Upcoming Milestones* 27 IntegraSyn TM INM - 755 for EB INM - 088 for Glaucoma * Latest best estimates. InMed is in frequent communication with our vendors and collaborators to monitor the COVID - 19 situation and ‘return - to - work’ guidelines. Corporate Presentation January 2021 • Continue
Slide 28: Board of Directors
28 Board of Directors 28 William Garner, MD Founder of EGB Ventures LLC (Chairman) Andrew Hull Former VP of Global Alliances at Takeda Pharmaceuticals Eric A. Adams President and CEO of InMed Pharmaceuticals • 25+ years’ experience as biotech entrepreneur • Director / F ou n d er , TRYP Therapeutics
Slide 29: Scientific Advisory Board
29 Scientific Advisory Board 29 Mauro Maccarrone, PhD Steven Dinh, ScD Vikramaditya G. Yadav, PhD • Prof. and Chair, Biochemistry & Molecular Biology at Campus Bio - Medico, University of Rome • Former President, International Cannabinoid Research Society and recipient of their 2016 Mechoulam Award
Slide 30: Financial Snapshot
30 Financial Snapshot 30 :IN Previous Close (202 1 - 01 - 05 ) US$ 3.51 C$ 4.44 52 - week High (incl. OTCQX listing) US$ 9.70 C$ 12.87 52 - week Low (incl. OTCQX listing) US$ 2.98 C$ 3.77 Avg. Daily Volume ( Trailing 50 Days ) 9 9,347 2 7,779 Market Cap, I/O (202 1 - 01 - 05 ) US$ 24.6 M C $31.1 M S
Slide 31: InMed at a Glance
31 InMed at a Glance 31 Diverse pipeline across a spectrum of diseases with high unmet medical needs Robust, innovative and disruptive IntegraSyn TM m a nu f a c turing approach World class leadership with successful track record in drug development and commercialization Multiple significant catalys
Slide 32: Thank You!
Thank You! Eric A. Adams Chief Executive Officer eadams@inmedpharma.com +1 - 604 - 669 - 7207 Bruce S. Colwill Chief Financial Officer bcolwill@inmedpharma.com +1 - 604 - 669 - 7207 www.inmedpharma.com :IN :I NM
InMed Pharmaceuticals — Investor Presentation (January 2021) on 6ix